{"id":"axiron-testosterone-topical-solution","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Application site reactions (irritation, erythema)"},{"rate":"5-10","effect":"Acne"},{"rate":"1-5","effect":"Polycythemia"},{"rate":"1-3","effect":"Gynecomastia"},{"rate":"2-5","effect":"Headache"},{"rate":"1-3","effect":"Mood changes"}]},"_chembl":{"chemblId":"CHEMBL1200335","moleculeType":"Small molecule","molecularWeight":"400.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Axiron is a topical solution containing testosterone that is absorbed through the skin, bypassing first-pass hepatic metabolism. It restores physiological testosterone levels in men with hypogonadism, thereby improving symptoms such as low libido, erectile dysfunction, fatigue, and mood disturbances. The transdermal delivery system provides steady-state hormone levels with once-daily application.","oneSentence":"Axiron delivers testosterone transdermally to replace deficient testosterone levels in hypogonadal men.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:04.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone replacement therapy in adult males with hypogonadism"}]},"trialDetails":[{"nctId":"NCT02722278","phase":"PHASE3","title":"A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","sponsor":"Clarus Therapeutics, Inc.","startDate":"2016-03","conditions":"Hypogonadism","enrollment":222},{"nctId":"NCT01893281","phase":"PHASE4","title":"The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Hypogonadism","enrollment":78},{"nctId":"NCT00702650","phase":"PHASE3","title":"A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Hypogonadism","enrollment":155},{"nctId":"NCT00857454","phase":"PHASE3","title":"A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-10","conditions":"Hypogonadism","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Axiron solution"],"phase":"phase_3","status":"active","brandName":"Axiron Testosterone Topical Solution","genericName":"Axiron Testosterone Topical Solution","companyName":"Clarus Therapeutics, Inc.","companyId":"clarus-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Axiron delivers testosterone transdermally to replace deficient testosterone levels in hypogonadal men. Used for Testosterone replacement therapy in adult males with hypogonadism.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}